About: Principals & Senior Staff

Peter J. Levine, Esq. President & CEO	Ben A. Hitt, Ph.D. Chief Scientist Emeritus	Reid G. Adler, Esq. EVP & Chief Legal Officer
Brian Mansfield, Ph.D. VP Research & Development	Ping F. Yip, Ph.D. VP Bio-Computing	Annette Fribourg, Esq. VP Government & Public Relations
Greg P. Bertenshaw, Ph.D. Director New Technology	Paolo Lecchi, Ph.D Director Mass Spectrometry	John M. Peltier, Ph.D. Senior Director of Spectrometry
Partha Seshaiah, Ph.D. Director Clinical & Collaborative Research

 

Peter J. Levine, Esq.

President & CEO
Contact

Peter Levine is co-founder of Correlogic Systems, Inc. Along with Dr. Ben Hitt, he is co-inventor of the patented "Hidden Patterns" approach to disease detection, and co-author of Correlogic's first three peer-reviewed scientific papers.

Mr. Levine is an attorney with a wide range of business development experience including domestic and international software and pharmaceutical licensing. His past experience includes work with multinationals on technology transfer issues and the creation of market entry strategies for consumer and capital goods.

The origins of Correlogic can be traced to Mr. Levine's early career as a trial attorney specializing in the creation and use of complex databases, including the evaluation of data "patterns" and the presentation of computer-generated evidence in litigation. He worked for the Departments of Justice and the Office of the U.S. Attorney, as well as Health, Education and Welfare.

Mr. Levine served as General Counsel of the U.S. Senate Subcommittee on Intergovernmental Relations, for Senator James Sasser. He then entered private practice, specializing in intellectual property and computer software. Clients included software firms such as Media Cybernetics and Litigation Support Services.

Mr. Levine also developed an international trade and investment consulting company, TransNational, eventually leaving the practice of law to concentrate on the new company. At TransNational, Mr. Levine developed such successful ventures as computer software and technology licensing in Japan; the licensing and sale of pharmaceutical and consumer products in Argentina; and the sale of industrial products in Western Europe and Japan. He has also advised companies and government agencies such as Mitsubishi, the Japanese Ministry of International Trade and Industry, the Japan External Trade Organization, Pharmavite/Otsuka Pharmaceutical, Laboratorios Bernabo and Finadiet, 3M Corporation, and the U.S. Department of Commerce.

Mr. Levine received his J.D. from New England School of Law and his B.A. in political science from Fairleigh Dickinson University.

Ben A. Hitt, Ph.D.
Chief Scientist Emeritus
Contact

Dr. Ben Hitt is co-founder of Correlogic Systems, Inc. Along with Peter Levine, he is co-inventor of the pattern recognition approach to disease detection. He is also the inventor of Correlogic's proprietary Proteome Quest^® software that is designed to analyze patterns in human blood proteins to detect disease. He is a nationally recognized expert in data mining and pattern recognition solutions. He is the inventor and patent holder of numerous algorithms and computer programs. Dr. Hitt’s works include inventions for analyzing disparate data streams, near real-time analysis of audio and text information streams, applications for the detection of credit card fraud, and optimization solutions for direct marketing problems.

Prior to his work at Correlogic, Dr. Hitt served as Senior Principal Software Engineer for Raytheon Systems, where he developed national security applications for his algorithmic work.

Dr. Hitt began his career as a biochemist specializing in drug metabolism and biochemical genetics. He became a Consulting Assistant Professor of Anesthesiology at Stanford University Medical School and Assistant Professor of Anesthesiology the University of Cincinnati Medical School, as well as a research chemist for the Veterans Administration Medical Center at Palo Alto.

He later held positions with Neuralware Inc., Advanced Software Applications, and American Heuristics, which he also co-founded. During this period, he developed and expanded his concepts of employing algorithms in data mining and other complex problem-solving applications. Progressing from his initial work with neural networks, Dr. Hitt incorporated genetic algorithms and related analytical techniques into his later inventions.

Hitt was a post-doctoral research associate at Stanford University Medical School. He received his Ph.D. in Biochemistry from West Virginia University in 1970, and his B.S. in Biology and Chemistry from West Liberty State College, in West Virginia, in 1966. He has published over 30 scientific papers based on his research and development experience.

 

Reid G. Adler, Esq.
EVP & Chief Legal Officer
Contact

Reid Adler is responsible for Correlogic's overall legal affairs. He manages the company's patent portfolio and works closely with the President on business development. He has served on Correlogic's Board since 2003 and before that was outside counsel to the company. Prior to joining Correlogic's staff, Mr. Adler was General Counsel for the nonprofit genomics research organization, the J. Craig Venter Institute, and its nonprofit affiliates, the J. Craig Venter Science Foundation and The Institute for Genomic Research. Additionally, he served as corporate Secretary for the Venter Institute and Venter Foundation. Previously, he was a partner at Morgan, Lewis & Bockius LLP where he was a co-leader of the firm's Life Sciences Practice Group and head of the biotechnology patent practice. His diverse client base included pharmaceutical and biotech companies and academic institutions, which he counseled on technology transfer and licensing, strategic management of technology assets, due diligence aspects of acquisitions, scientific misconduct and patent-related matters.

Mr. Adler was Director of the Office of Technology Transfer (OTT) at the National Institutes of Health during its implementation of the Federal Technology Transfer Act. He was involved with development of technology transfer policies and procedures, and won the NIH Director's Award for integrating the patent, licensing and marketing operations in the OTT. He left NIH in 1993 to return to private practice.

Mr. Adler received a JD from George Washington University in 1982 and a BS in Chemistry from the University of Maryland in 1975. He clerked for the Honorable Giles S. Rich at the Court of Appeals for the Federal Circuit. He has taught courses in biotechnology law and policy as well as technology management at Johns Hopkins, George Washington University Law School and the FAES graduate school at NIH, and has published extensively and testified before Congress on these topics. Mr. Adler served on the Committee on Science, Engineering and Public Policy (2000-2006) which is an advisory Board of the American Association for the Advancement of Sciences, and was a member of the Steering Committee of the Bioscience Alliance of the Montgomery County (Maryland) High Technology Council.

Brian Mansfield, Ph.D.
VP Research & Development
Contact

Dr. Mansfield is responsible for the development of new diagnostic tests, including the current initiative with Breast Cancer. Dr. Mansfield has a broad scientific background and over 27 years of experience spanning physical chemistry, biochemistry, molecular biology and genetics. Prior to joining Correlogic Dr. Mansfield spent 5 years as a Senior Scientist in Protein Development at Human Genome Sciences Inc. Prior to this, Dr. Mansfield spent 12 years as a tenured Professor of Eukaryotic Genetics at Massey University, New Zealand and 3 years as a Visiting Professor at Georgetown University. For the last 14 years he has also held a joint position as an Adjunct Scientist with the NICHD, NIH.

Dr. Mansfield's early research focused on the discovery, cloning, expression, purification and functional characterization of the Pregnancy Specific Glycoproteins (PSG), novel members of the Carcinoembryonic Antigen (CEA) family. He was the first to demonstrate a biologically active motif in a PSG and describe their functional evolution. At HGSI he was responsible for the development of mammalian cell lines expressing novel recombinant proteins and their purification. He played key roles on several major pre-clinical projects and was the Project Leader for Lead Optimization, responsible for the discovery and characterization of pharmaceutically-relevant proteins, forming the HGSI product pipeline. His ongoing collaborations with Dr Janice Chou at the NICHD, NIH focus on metabolic disease, elucidating the molecular basis and pathophysiology of the Type I Glycogen Storage Diseases.

Dr. Mansfield received an Honors degree in Physical Chemistry from Canterbury University in 1977 and a Ph.D. in Biochemistry from the University of Otago, New Zealand in 1982. He was a Fogarty International Research Fellow, in molecular genetics, from 1982 to 1985 with the Nobel Laureate Professor Daniel Nathans at the Johns Hopkins University School of Medicine, Baltimore. Dr. Mansfield is on the editorial board of Current Molecular Medicine. He has served on the boards of several Medical Research Foundations and community organizations. He holds a number of patents and over 35 peer-reviewed publications. He is the co-lead author on Correlogic's two most recent peer-reviewed publications.

Ping F. Yip, Ph.D.
VP Bio-Computing
Contact

Dr. Yip is in charge of Correlogic’s bio-computing and software development.

For more than 15 years, Dr. Yip has been engaged in a wide range of research and development activities in the bio-computing arena, including work in computational structural biology, computational chemistry, NMR, X-ray Crystallography, mass spectrometry, and computational genomics. Dr. Yip is the author of many peer-reviewed papers spanning a range of topics, from NMR and mass spectroscopy, to biochemistry, and to genomics. He has invented algorithms that are at the core of many commercial products.

Prior to joining Correlogic, Dr. Yip was Director of Bioinformatics at HK Pharmaceuticals, Inc. where he headed the IT and software group, focusing on the development of mass spectrometry proteomics tools. Prior to his position at HK, he was Director of Bioinformatics at Sequenom, Inc.

Dr. Yip has also held positions at Scripps Clinic and Research Institute and the University of California at San Diego. He received his Ph.D. in Mathematical Physics from the University of Chicago, and his B.A. in Physics and Mathematics from Hamilton College.

Annette Fribourg, Esq.
VP Government & Public Relations
Contact

Ms. Fribourg is responsible for congressional and government agency relations, and corporate communications.

Ms. Fribourg has extensive lobbying and overall government relations experience. After receiving her law degree from George Washington University, she held positions in the private and public sectors. She served as legislative counsel to Senator John H. Chafee (RI) and Senator Jacob K. Javits (NY). In these positions, she specialized in financial, trade and housing issues, and developed major legislative initiatives for the senators in each of these areas. She was an officer of the Federal Reserve serving under Chairman Paul A. Volcker, where she was also responsible for banking and trade matters.

Immediately prior to joining Correlogic Systems, Ms. Fribourg held the positions of Vice President of Congressional Relations and Vice President of Regulatory Activities with Fannie Mae, in Washington, DC. She headed government relations during the passage of crucial legislation modernizing the corporation's financial regulatory structure. She was responsible for the passage of several bills financially critical to the corporation, and for the successful strategy in connection with legislative and regulatory challenges to the corporation. She created an advocacy and research division within Fannie Mae that became the center for addressing academic and media challenges.

Ms. Fribourg has also held positions as lobbyist for the National Association of Manufacturers and as a specialist in privacy legislation for the National Telecommunications and Information Administration.

 

Ms. Fribourg attended Dartmouth College and Tufts University, from which she earned her B.A. degree, and the National Law Center of George Washington University, from which she earned her J.D. degree. Ms. Fribourg is a member of the New York Bar.

 

Greg P. Bertenshaw, Ph.D.
Director New Technology
Contact

As part of Correlogic’s Research and Development Team, Dr. Bertenshaw is involved in method optimization, reproducibility of analytical platforms, the development of analytical tools, and the analysis of spectral files and modeling data.

Prior to joining Correlogic, Dr. Bertenshaw was a Scientific Director at Clearant, Inc. His main focus at Clearant was the development of novel processing methods to ensure the properties of various biological products were maintained while achieving robust pathogen inactivation using high doses of gamma radiation. Dr. Bertenshaw was involved in designing, optimizing and validating assays for functional studies of diverse therapeutics that included transgenic proteins, purified proteins, blood products/derivatives and human allograft tissues.

Dr. Bertenshaw received his B.S. in Biochemistry from the University of Manchester in the United Kingdom and his Ph.D. in Biochemistry and Molecular Biology from the Pennsylvania State University. His doctorate studies at Pennsylvania State University as well as work at A. I. duPont Institute, focused on the structure-function relationship of several proteolytic enzymes including meprins A and B, and cathepsin L. Dr. Bertenshaw has co-authored 12 peer-reviewed manuscripts and book chapters describing his research.

 

Paolo Lecchi, Ph.D.
Director Mass Spectrometry
Contact

Dr. Lecchi heads Correlogic’s new laboratory facility. 

Dr. Lecchi has over fifteen years experience in the development of analytical methods for the purification and characterization of biopolymers and pharmaceuticals by mass spectrometry. He is the author of more than 25 peer-reviewed articles in analytical biochemistry.  Before joining Correlogic, Dr. Lecchi was Associate Research Professor in the Department of Pharmacology at the George Washington University and the Director of the Proteomics Core Facility of the George Washington University Medical Center.

Previously, Dr. Lecchi was a Postdoctoral fellow in the laboratory of Bioorganic Chemistry of the NIDDK, at the NIH, where he was involved in several studies of the characterization of biological moieties. In an earlier postdoctoral experience, Dr. Lecchi also was engaged in research at the University of Texas Medical School in Houston. Dr. Lecchi received his Ph.D. degree in Experimental Pharmacology in 1991 from the University of Milan, Italy.

 

John M. Peltier, Ph.D.
Senior Director of Spectrometry
Contact

Dr. Peltier is engaged in the development of mass spectrometric and other spectroscopic methods for Correlogic’s diagnostic and other applications.  His responsibilities include optimization of spectroscopic methods, data analysis methods and supporting software development.

Dr. Peltier has over 20 years of experience in mass spectrometry and analytical methods development, including characterization of lipid and carbohydrate components of bacterial cell surface antigens, characterization of post-transcriptionally modified RNA, qualitative and quantitative analysis of peptides and proteins, protein interaction analysis and characterization of the metabolism of small molecules for drug development.

Prior to joining Correlogic, Dr. Peltier conducted research and development at Prolexys Pharmaceuticals, including MS-based target discovery, high throughput assay development for kinases and other molecular targets.  He also ran Prolexys’ discovery ADME/PK program.  In his previous position at Applied Biosystems Dr. Peltier was involved the development of MS platforms, integrated analysis systems, software tools and reagent tools for the analysis of proteins and small molecules.

Dr. Peltier received his BS and Ph.D. degrees in Chemistry from McMaster University in Canada. He conducted his postdoctoral research at the University of Utah, in the laboratory of Dr. James McCloskey, where he investigated the structure of modified ribonucleic acids.  He has 15 peer-reviewed publications and is a co-inventor on a number of filed patents.

Partha Seshaiah, Ph.D.
Director Clinical & Collaborative Research
Contact

Dr. Seshaiah is in charge of developing study protocols, training staff in the execution of study protocols and overseeing the performance of studies at trial sites. In this capacity, he is also responsible for sample management, and for devising clinical trial data collection systems.

Prior to joining Correlogic, Dr. Seshaiah was a Research Scientist in the Bioinformatics group at CuraGen Corporation. At CuraGen, he served as primary bioinformatics liaison with collaborative partners such as Bayer AG, Biogen, Dupont/Pioneer Hi-Bred International, Hoffman-La Roche, Monsanto, and Ono Pharmaceuticals. He also presented CuraGen's genomics and proteomics platforms to executive and scientific audiences and was charged with integrating scientists' feedback with the software development cycle at CuraGen.

Dr. Seshaiah received his Ph.D. from the Biochemistry, Cellular and Molecular Biology Program at the Johns Hopkins University School of Medicine, studying genes involved in organ formation and development. He received his S.B. in Biology from the Massachusetts Institute of Technology.

 

Back to top >